Creative Biolabs provides zebrafish patient-derived xenograft model services to rapidly compare live biotherapeutic candidates and combination regimens against individual tumor samples, generating imaging, efficacy, toxicity, and immune-related evidence for more confident candidate prioritization. Our study designs help oncology microbiome teams select promising conditions before committing to longer mammalian validation programs.
Oncology microbiome developers and personalized efficacy teams need an in vivo model that can reveal differences among tumor samples, live biotherapeutic candidates, and combination regimens without waiting months for traditional xenografts. Limited patient material, slow model expansion, and difficult cross-program comparisons can delay the decision to advance or stop a candidate.
Zebrafish patient-derived xenografts combine rapid engraftment with fluorescent visualization of tumor growth, invasion, angiogenesis, and treatment response. Without a consistent experimental framework, teams may advance conditions that look active in vitro but lack a useful tumor-context signal in vivo, or miss promising combinations. Creative Biolabs provides a study-ready zPDX service that connects model establishment, controlled dosing, quantitative imaging, safety observations, and decision-oriented reporting in one coordinated program.
Use patient-derived tumor material to rank LBP monotherapies and combinations, identify heterogeneous response patterns, and nominate focused conditions for confirmatory mammalian studies.
Creative Biolabs designs zPDX studies around the client’s tumor material, microbial modality, comparator strategy, and downstream development decision. Each project is configured to preserve biological relevance while producing consistent, interpretable evidence across treatment groups.
We review sample format and availability, prepare patient-derived cells or tissue, select an appropriate implantation site and zebrafish stage, label tumor material, and establish acceptance criteria. Engraftment rate, baseline fluorescent tumor burden, morphology, viability, and group balance can be documented before treatment allocation.
Study arms may compare live biotherapeutic candidates, selected dose levels, viability states, delivery routes, vehicle controls, anticancer comparators, or LBP-plus-drug combinations. We align exposure timing and group structure with the proposed mechanism, practical handling limits, and the exact ranking question.
Serial fluorescence imaging provides quantitative measures of relative tumor area or signal, cell dissemination, invasion, and metastatic spread. Where suitable transgenic reporter lines are available, vascular interactions and angiogenic potential can be observed in real time, creating an efficient view of tumor behavior under treatment.
Gross morphology, survival, edema, developmental abnormalities, and tolerability observations can be integrated with efficacy measurements. Depending on the study hypothesis and model configuration, immune-cell recruitment, inflammatory signals, or tumor-microenvironment markers can be added to distinguish activity from nonspecific toxicity.
A zPDX screen is most valuable when the readouts answer an explicit advancement question. We normalize image-derived measures, compare treatment effects across relevant controls, examine response heterogeneity, and present a transparent candidate ranking with documented limitations.
| Service Module | Typical Output | Decision Supported |
|---|---|---|
| Model QC | Engraftment and baseline-balance summary | Proceed with a qualified model |
| Efficacy imaging | Tumor burden and dissemination analysis | Rank candidates and combinations |
| Safety observations | Tolerability and morphology dataset | Separate efficacy from toxicity |
| Integrated report | Methods, results, images, and ranking rationale | Select mammalian validation conditions |
A gated workflow protects scarce tumor material and keeps the study focused on the next development decision.
Define tumor source, LBP modality, combinations, controls, and ranking criteria.
Process, label, implant, and qualify patient-derived tumor material.
Administer qualified candidates and comparator regimens under controlled conditions.
Measure tumor response, dissemination, tolerability, and selected immune signals.
Integrate evidence and nominate conditions for mammalian confirmation.
Zebrafish models have supported studies of tumorigenesis and invasion in breast and prostate cancers, hepatocellular carcinoma, and other solid and hematologic malignancies. Fluorescently labeled tissues provide a window into cancer-cell growth, spread, and interaction with the tumor microenvironment.
In vivo drug screening
Therapeutic target testing
Biomarker hypothesis support
Tumor-response stratification
Combination prioritization
Recent research established zebrafish tumor xenograft models from cryopreserved non-muscle-invasive bladder cancer specimens and compared bacterial BCG treatment responses with available patient outcomes. The investigators implanted fluorescently labeled patient tumor cells into larvae, quantified relative tumor size after treatment, and observed response differences among individual samples. The work is directly relevant to LBP-oriented discovery because it demonstrates how a live microbial intervention can be tested against patient-derived tumor material in a rapid vertebrate model.
The published data indicate that patient-specific response patterns can be resolved while tumor burden and tolerability are assessed within the same experimental platform, although broader validation is still necessary. Creative Biolabs can translate this model logic into customized candidate and combination screens with defined controls, image-based endpoints, and transparent ranking criteria. These studies are designed for preclinical research decisions and can nominate focused hypotheses and treatment conditions for subsequent mammalian evaluation.
Transplanting human cancer cells into zebrafish creates an in vivo environment for real-time visualization of tumor-cell interactions. Creative Biolabs adds study-design discipline, LBP handling experience, quantitative endpoints, and a clear translational handoff to this rapid model.
Short experimental windows support timely screening and iteration.
Transparent larvae enable longitudinal visualization of tumor behavior.
The platform can work with limited patient-derived material.
Miniaturized studies require relatively small candidate quantities.
Reporter and immune-deficient lines can address distinct questions.
Ranked outputs focus follow-up mammalian validation on the strongest conditions.
Share your tumor source, LBP candidate format, comparator strategy, and priority endpoints. Our team will shape a zPDX study around the decision your program needs to make next.
Extend an initial zPDX screen with broader zebrafish discovery support, cancer efficacy models, focused efficacy evaluation, or integrated preclinical safety and efficacy assessment.
Yes, when the candidate, tumor material, route, and scientific question are compatible with the model. Zebrafish xenografts can compare tumor response after exposure to live microbial candidates or microbial-plus-drug combinations. Study controls must distinguish candidate-specific activity from handling effects, background regression, and nonspecific toxicity. Feasibility is assessed case by case.
They can provide valuable rapid, comparative in vivo evidence. The platform is particularly useful for ranking treatment conditions, visualizing tumor behavior, and identifying response heterogeneity before larger mammalian studies. Results should be interpreted within the model’s scope and used as part of an integrated preclinical evidence package rather than as a standalone prediction.
Depending on availability and quality, studies may begin with dissociated fresh or cryopreserved patient tumor material, selected tumor-cell preparations, or established cancer cell lines for assay development. Sample viability, cell yield, labeling compatibility, biosafety requirements, and engraftment performance are reviewed before the definitive screen.
Core endpoints may include relative tumor burden, growth or regression, dissemination, invasion, survival, morphology, edema, and tolerability. Angiogenesis or immune-related readouts can be considered when an appropriate reporter line, staining strategy, and study hypothesis are available. The endpoint set is finalized during study design.
We use the zPDX dataset to identify the most informative candidate, dose, combination, schedule, and biomarker hypotheses for follow-up. The report separates robust findings from exploratory observations so a mammalian study can focus on the conditions with the strongest evidence and the most important remaining uncertainties.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2026 Creative Biolabs. All Rights Reserved.
